Joyce Mhlanga

Joyce Mhlanga

Auto-generated profile, based on publicly available information

Joyce Mhlanga

Washington University School of Medicine in St. Louis

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
JMJoyce Mhlanga
Joyce Mhlanga
HLHollie Lai
Hollie Lai
AAAdina Alazrkai
Adina Alazrkai
SCSteve Y Cho
Steve Y Cho
HNHelen Nadel
Helen Nadel
KMKathleen McCarten
Kathleen McCarten

29 May 2019 in British Journal of Radiology
Verified
Journal Article
Closed access
RTRichard Tsai
Richard Tsai
AMAaron Mintz
Aaron Mintz
MLMichael Lin
Michael Lin
JMJoyce Mhlanga
Joyce Mhlanga
ACAdeeti Chiplunker
Adeeti Chiplunker
KFKathryn Fowler
Kathryn Fowler
Objective: The aim of this study is to determine the interrater agreement in a clinical practice environment for the most commonly used magnetic resonance enterography (MRE) features of Crohn’s disease (CD). Methods: CD patients with MRE’s before and after treatment were retrospectively identified using search queries over a 7-year period (May 2017–September 2017). MRE features of CD comprising components of multiple CD scoring indices were scored by radiologists in the same segment of bowel. Agreement for nominal categorical and continuous variables was assessed using a κ and interclass correlation coefficients, respectively. Results: 80 scans comprised the study population. Moderate interrater agreement was seen in both the pre- and post-treatment MRE’s for presence of diffusion restriction (к = 0.43, 0.48; pre- and post-treatment), stricturing disease (к = 0.51, 0.52), overall degree of severity (к = 0.49, 0.59). Substantial agreement was seen in pre- and post-treatment scans for length of involvement (interclass correlation coefficient = 0.67, 0.61). The presence of mucosal ulceration had no agreement (к = −0.07, –0.042). Conclusion: Many MRE features of active CD comprising the major CD scoring indices are reproducible when interpreted by non-CD focused abdominal radiologists. However, the presence of mucosal ulcerations had no agreement and may need more investigation before including this feature as a driver in therapeutic decision making. Advances in knowledge: Demonstrates the unreliability of mucosal ulceration by non-CD focused abdominal radiologists, targeting a potential area for future education. Key Points The majority of MRE findings incorporated in to many CD scoring indices have fair to moderate inter-rater agreement even when read by non-MRE expert radiologists. Substantial agreement was seen in the length of involved bowel, but this feature is only incorporated in to one of the CD scoring indices. Presence of mucosal ulcerations had no interrater agreement in our study—a feature which is heavily weighted by several CD scoring indices. Research should be focused bridging those features which have poor interrater agreement.

1 August 2023 in RadioGraphics
Verified
Journal Article
Closed access
ZTZiad Tarcha
Ziad Tarcha
KKKaterina S. Konstantinoff
Katerina S. Konstantinoff
SISEMRA INCE
SEMRA INCE
TFTyler J. Fraum
Tyler J. Fraum
ESElizabeth A. Sadowski
Elizabeth A. Sadowski
MIMalak Itani
Malak Itani
Fluorine 18-fluorodeoxyglucose (FDG) PET and MRI independently play a valuable role in the management of patients with gynecologic malignancies, particularly endometrial and cervical cancer. The PET/MRI hybrid imaging technique combines the metabolic information obtained from PET with the excellent soft-tissue resolution and anatomic details provided by MRI in a single examination. MRI is the modality of choice for assessment of local tumor extent in the pelvis, whereas PET is used to assess for local-regional spread and distant metastases. The authors discuss the added value of FDG PET/MRI in imaging gynecologic malignancies of the pelvis, with a focus on the role of FDG PET/MRI in diagnosis, staging, assessing treatment response, and characterizing complications. PET/MRI allows better localization and demarcation of the extent of disease, characterization of lesions and involvement of adjacent organs and lymph nodes, and improved differentiation of benign from malignant tissues, as well as detection of the presence of distant metastasis. It also has the advantages of decreased radiation dose and a higher signal-to-noise ratio of a prolonged PET examination of the pelvis contemporaneous with MRI. The authors provide a brief technical overview of PET/MRI, highlight how simultaneously performed PET/MRI can improve stand-alone MRI and PET/CT in gynecologic malignancies, provide an image-rich review to illustrate practical and clinically relevant applications of this imaging technique, and review common pitfalls encountered in clinical practice. ©RSNA, 2023 Quiz questions for this article are available in the supplemental material.

1 February 2018 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
JMJoyce C. Mhlanga
Joyce C. Mhlanga
ACAlin Chirindel
Alin Chirindel
MLMartin A. Lodge
Martin A. Lodge
RWRichard L. Wahl
Richard L. Wahl
RSRathan M. Subramaniam
Rathan M. Subramaniam
Objective The aim of this study was to determine whether various fluorine-18-fluorodeoxyglucose PET/CT-derived parameters used in oncology vary significantly depending on the interpretation software systems used in clinical practice for multiple human solid tumors. Patients and methods A total of 120 fluorine-18-fluorodeoxyglucose PET/CT studies carried out in patients with pancreatic, lung, colorectal, and head and neck cancers were evaluated retrospectively on two different vendor software platforms including Mirada and MIMVista. Regions of interest were placed on the liver to determine the liver mean standardized uptake value at lean body mass (SUL) and on each tumor to determine the SULmax, SULpeak. Total lesion glycolysis (TLG) and metabolic tumor volume (MTV) were determined using fixed thresholds of 50% of SULmax and SULpeak. Inter-reader, intersystem intraclass correlations, systematic bias, and variability reflected by the 95% limits of agreement, and precision were determined. Results There was excellent inter-reader reliability between the readers and the two software systems, with intraclass correlations more than 0.9 for all PET metrics, with P values less than 0.0001. The bias and SD on Bland–Altman analysis between the two software platforms for tumor SULmax, SULpeak, Max50MTV, and Peak50MTV, respectively, for Reader 1 were −1.52±2.24, 0.80±3.67, −0.80±13.01, and −4.49±20.6. For Reader 2, the biases were −1.62±1.95, 0.18±3.60, −0.27±4.64, and −3.13±8.30. The precision between the two systems was better for SULmax and SULpeak, with less variance observed, than for volume-based metrics such as Max50MTV and Peak50MTV or TLG. Conclusion Excellent correlation has been found between two tested software reading platforms for all PET-derived metrics in a dual-reader analysis. Overall, the SULmax and SULpeak values had less bias and better precision compared with the MTV and TLG.

14 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SJShama Jaswal
Shama Jaswal
VSVanessa Sanders
Vanessa Sanders
PPPriyanka Pullarkat
Priyanka Pullarkat
STStephanie Teja
Stephanie Teja
ASAmber Salter
Amber Salter
JIJoseph E. Ippolito
Joseph E. Ippolito
In many cancers, including lymphoma, males have higher incidence and mortality than females. Emerging evidence demonstrates that one mechanism underlying this phenomenon is sex differences in metabolism, both with respect to tumor nutrient consumption and systemic alterations in metabolism, i.e., obesity. We wanted to determine if visceral fat and tumor glucose uptake with fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) could predict sex-dependent outcomes in patients with diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis of 160 patients (84 males; 76 females) with DLBCL who had imaging at initial staging and after completion of therapy. CT-based relative visceral fat area (rVFA), PET-based SUVmax normalized to lean body mass (SULmax), and end-of-treatment FDG-PET 5PS score were calculated. Increased rVFA at initial staging was an independent predictor of poor OS only in females. At the end of therapy, increase in visceral fat was a significant predictor of poor survival only in females. Combining the change in rVFA and 5PS scores identified a subgroup of females with visceral fat gain and high 5PS with exceptionally poor outcomes. These data suggest that visceral fat and tumor FDG uptake can predict outcomes in DLBCL patients in a sex-specific fashion.

14 September 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
NMNichole M. Maughan
Nichole M. Maughan
JGJose L. Garcia‐Ramirez
Jose L. Garcia‐Ramirez
FHFrederick S Huang
Frederick S Huang
DWDaniel N. Willis
Daniel N. Willis
AIAmir Iravani
Amir Iravani
JZJacqueline E. Zoberi
Jacqueline E. Zoberi